Table 2.
Health care utilization and mortality rates by type of hematopoietic cell transplant
| Health care use and mortality rates | No HCT (n = 69) | Allogeneic‐HCT (n = 57) | Autologous HCT (n = 28) | Total (n = 154) | P‐value |
|---|---|---|---|---|---|
| Hospitalization, n (%) | 30 (43) | 44 (77) | 20 (71) | 94 (61) | <0.001* |
| ICU admission, n (%) | 21 (30) | 15 (26) | 6 (21) | 42 (27) | 0.65 |
| Mechanical ventilation, n (%) | 12 (17) | 12 (21) | 6 (21) | 30 (19) | 0.83 |
| 30 d mortality (from LRTI diagnosis to death), n (%) | 11 (16) | 11 (19) | 4 (14) | 26 (17) | 0.85 |
| 60 d mortality (from LRTI diagnosis to death), n (%) | 18 (26) | 16 (28) | 5 (18) | 39 (25) | 0.59 |
ICU, intensive care unit; LRTI, lower respiratory tract infection; RSV, respiratory syncytial virus. Patients without HCT were less likely to be hospitalized (in bold).
This article is being made freely available through PubMed Central as part of the COVID-19 public health emergency response. It can be used for unrestricted research re-use and analysis in any form or by any means with acknowledgement of the original source, for the duration of the public health emergency.